Transcript Policy TF Quarterly Update

Policy TF
Quarterly Update
Mar. 30, 2011
BOD Sponsors : Mr. Jinho Kim
Mr. Sangjin Park
Agenda
• Global Budget System
• Monthly updates
– Decision from last meeting
– R&D Environment Comparison(2010)
– DTC
• Other committee activity updates
Organization
BOD sponsor
Company leader
Jinho Kim (GSK)
Key Lee (MSD)
Sangjin Pak(Astra Z.)
Members
Taejin Ham (Lilly)
Tae Ho Roh (Janssen)
Young Joo Song (Janssen)
Yeon Sim Jeong (Astra Z.)
Sung Hye Hwang (Pfizer)
Won Do (sanofi-aventis)
Hae-Kyung Myung (GSK)
Sung-ho Kim(GSK)
IB Kim (KRPIA)
Project Updates
• R&D environment comparison
– Completed and distributed report to member companies
• Key contents : complicate formulary, lower incentive level and exclusion of
trusted R&D activities
• Policy suggestions : Easing the formulary, increasing incentive level and
inclusion of trusted R&D activities
– Discussed with Regulatory Reform Office(RRO) on the details of the
report
– Action plans
• RRO will organize a meeting with related government offices on Mar. 29 :
either MEST or MEK, or both
• Mr. Sean Kim(GSK) and a nominee from R&D committee will join
• Key KRPIA talking points
–
–
–
–
Comparatively narrower definition of R&D activities
Stricter requirements for R&D expenses : research center or department
Relatively lower incentive level (formulary)
Incentives to trusted R&D expenses from HQ
Project Updates
• Global Budget System / Reference Pricing
– Objectives : Understanding and proactive preparation for the
potential policy introduction
– Contents
• Understanding on medical service and pharmaceutical
reimbursement systems in OECD countries : independent variables
• Analyzing policy impacts by economic(regression) and marketing
(conjoint, 5-force, 3C, PEST) analytical models
• Policy scenario analysis of the impacts on NHI finance,
pharmaceutical industry, R&D, employment : dependent variables
– Depending on MOHW schedule, earlier data preparation on GBS
and Reference Pricing
Project Updates
• DTC introduction
– Broadcasting industry change triggered the discussion of DTC
introduction
– KRPIA doesn’t have position on DTC introduction
– Objective
• Advanced study on the issue before DTC becomes boiling
– Contents
• Gathering fact based positions of both pro-DTC and anti-DTC
groups
• Points to consider
– Patient benefit
– Drug usage/quantity and drug expenditure pattern
– Price pattern
– No official KRPIA position until this stud completed
감사합니다.